Results 151 to 160 of about 6,539 (194)

Adenoma receptors and histologic characteristics determining management outcomes.

J Clin Endocrinol Metab
Wildemberg LE, Gadelha MR.
europepmc   +1 more source

Place of Cabergoline in Acromegaly: A Meta-Analysis [PDF]

Journal of Clinical Endocrinology and Metabolism, 2011
Context: Cabergoline is widely considered to be poorly effective in acromegaly. Objective: The aim of this study was to obtain a more accurate ...
Philippe Chanson, Patrick Maison, Chanson Philippe   +2 more
exaly   +2 more sources

Cabergoline Decreases Alcohol Drinking and Seeking Behaviors Via Glial Cell Line-Derived Neurotrophic Factor [PDF]

Biological Psychiatry, 2009
Background: Cabergoline is an ergotamine derivative that increases the expression of glial cell line-derived neurotrophic factor (GDNF) in vitro. We recently showed that GDNF in the ventral tegmental area (VTA) reduces the motivation to consume alcohol ...
Dorit Ron, Selena Bartlett, Patricia Janak   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Cabergoline

Expert Opinion on Pharmacotherapy, 2000
Cabergoline (CAB) (1-[(6-allelylergolin-8 beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethyl-urea) is an ergoline derivative with potent, selective and long-lasting inhibitory activity on prolactin (PRL) secretion acting on dopamine receptors present in pituitary lactotrophes.
COLAO, ANNAMARIA, LOMBARDI, GAETANO, ANNUNZIATO, LUCIO   +2 more
openaire   +3 more sources

Cabergoline in acromegaly

Pituitary, 2016
Acromegaly, a rare disease due to growth hormone (GH) hypersecretion by a pituitary adenoma, is associated with severe comorbidity and premature death if not adequately treated. The usual first-line treatment is surgery. Various drugs, including somatostatin receptor ligands, dopamine agonists and GH receptor antagonists, are now available for use if ...
Emmanuelle Kuhn, Philippe Chanson
openaire   +2 more sources

Cabergoline

Reactions Weekly, 2018
  +8 more sources